Published On: September 22nd, 2009
Against a backdrop of continued scrutiny about drug makers’ influence on doctors and medical education, GlaxoSmithKline announced today that it will no longer fund so-called medical-education programs offered by commercial providers.
Instead, beginning in 2010, it will fund only independent medical education programs “that are clearly designed to close gaps in patient care, and that demonstrate support for the optimal performance of healthcare professionals,” according to a company statement. This means only academic medical centers with “strong track records for delivering high quality programs” will receive future funding, the company adds on its blog.
Drug company funding of continuing medical-education programs hit $1.2 billion in 2006, raising concern about some doctor groups, including the American Medical Association, which has been trying to come up with a new ethics policy that would limit industry influence on continuing education for doctors.
Glaxo, like other pharmaceutical companies, have been making efforts to increase transparency by capping payments to physicians and reporting those payments publicly. It has also limited political donations.
Image: iStockphoto

Go here to read the rest:
Glaxo Curbs Funding to Commercial Medical-Education Programs



Did you know:





